In 2016, the company brought in an outside chief executive, Alan Naumann, formerly CEO of online fraud detection startup 41st Parameter, to expand the business
[1] Similar titration schedules are recommended for other GLP-1 agonists to help improve tolerability and adherence
It is usually administered once weekly or once monthly, depending on the dose and formulation
The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program provided the primary evidence base, showing continued efficacy without significant safety concerns emerging over extended use
Possible effects include: Loose or excess skin Fatigue Hair thinning Muscle loss (if not strength training) Gallbladder issues with rapid loss Nutrient deficiencies if diet is poor Most risks are reduced with gradual weight loss, adequate protein, strength training, and medical supervision